Conversations and Reactions around Severe Hypoglycemia (CRASH): US Results from a Global Survey of People with T1DM or Insulin-Treated T2DM and Caregivers

被引：2

作者：

Snoek, Frank J.

Jiletcovici, Alina

Bushnell, Donald M., III

Child, Christopher J.

Bajpai, Sanjay K.

Spaepen, Erik

Thomas, Josh

Balantac, Zaneta

Peyrot, Mark

Mitchell, Beth

机构：

来源：

DIABETES | 2019年 / 68卷

关键词：

D O I：

10.2337/db19-285-OR

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

285-OR

引用

页数：3

共 50 条

[41] Empagliflozin as Add-On to Basal Insulin for 78 Weeks Improves Glycemic Control With Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)
Rosenstock, Julio
Jelaska, Ante
Wang, Fei
Kim, Gabriel
Broedl, Uli C.
Woerle, Hans J.
DIABETES, 2013, 62 : A285 - A285
[42] Association of Treatment Persistence and Adherence With Real-World Outcomes Among Insulin-Treated Patients With Type 2 Diabetes Mellitus (T2DM)
Wei, Wenhui
Pan, Chunshen
Xie, Lin
Baser, Onur
DIABETES, 2012, 61 : A4 - A4
[43] Less hypoglycemia with exenatide versus insulin glargine, despite similar Hba1c improvement, in patients with T2dm adjunctively treated with metformin
Trautmann, Michael
Burger, Jude
Johns, Don
Brodows, Robert
Okerson, Ted
Roberts, Anthony
Barnett, Anthony
DIABETES, 2007, 56 : A45 - A45
[44] Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec
Lecumberri, Edurne
Ortega, Maite
Iturregui, Marta
Antonio Quesada, Jose
Vazquez, Clotilde
Orozco, Domingo
CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 1053 - 1059
[45] Glucagon Receptor Antagonist LY2409021 Does Not Impede Recovery From Insulin Induced Hypoglycemia in Patients With T2DM
Kelly, Ronan P.
Lim, Chay Ngee
Pratt, Edward
Loh, Mei Teng
Deeg, Mark
Fu, Haoda
Cui, Sherry
Garhyan, Parag
DIABETES, 2012, 61 : A256 - A256
[46] Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM)
Rosenstock, Julio
Nino, Antonio J.
Soffer, Joseph
Mallory, Jason M.
Erskine, Lois M.
Acusta, Andre
Dole, Jo F.
Carr, Molly
Home, Philip
DIABETES, 2018, 67
[47] Global Patterns of Treatment Changes among Patients with Type 2 Diabetes (T2DM) Treated with Insulin: Insights from the MOSA1c Observational Study
Davies, Melanie
Fan, Ludi
Ali, Ayad K.
Araz, Mustafa
Bain, Stephen C.
Beshya, Salem
Caballero, A. Enrique
Curtis, Bradley H.
Fernandes, Virginia
Linetzky, Bruno
Montenegro, Renan M., Jr.
Adame, Leonardo Mancillas
Matsuba, Ikura
Peng, Xiaomei
Polonsky, William H.
Tsoukas, Michael
Zhao, Zhenxiang
Ray, Kausik
DIABETES, 2017, 66 : A98 - A98
[48] Risk Factors and Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Basal Insulin in a US Managed Care System
Chou, Engels
Chung, Hsing-Wen
Wang, Hongwei
DIABETES, 2014, 63 : A66 - A67
[49] NEW INSULIN GLARGINE 300 U/ML: GLYCEMIC CONTROL AND HYPOGLYCEMIA IN A META-ANALYSIS OF EDITION CLINICAL TRIALS IN PEOPLE WITH T2DM
Ritzel, R. A.
Roussel, R.
Bolli, G. B.
Vinet, L.
Yki-Jarvinen, H.
DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A16 - A17
[50] REAL-WORLD INCIDENCE OF HYPOGLYCEMIA AND ASSOCIATED COSTS AMONG INSULIN GLARGINE-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Xie, L.
Wei, W.
Pan, C.
Baser, O.
VALUE IN HEALTH, 2012, 15 (07) : A493 - A493

← 1 2 3 4 5 →